

Date: 05th February, 2018

To,
The Manager,
Corporate Filings Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 540679

Symbol: SMSLIFE

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on 05th February, 2018.

With reference to the above subject, we would like to inform you that the Board of Directors of the Company at their meeting held on today, inter-alia considered and approved the Unaudited financial results for the Quarter ended on 31st December, 2017 along with the Limited Review Report as enclosed herewith.

Thereafter, the meeting was adjourned to 8th February, 2018 and the agenda items relating to the acquisition of API Manufacturing Company and Issue of Non-Convertible Preference shares or Non-Convertible Debentures will be considered at the adjourned meeting.

The Meeting commenced at 12.30 PM and concluded at 2.10 PM.

Please take the above information on your records.

Thanking You,

Yours Faithfully,

For SMS Lifesciences India Limited



Pavan Pise
Company Secretary


SMS LIFESCIENCES INDIA LIMITED

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Un-Audited Financial Results for the Quarter and 9 Months Ended 31st December, 2017

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			9 Months Ended	
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1	Revenue From Operations	6,647.74	5,104.37	6,109.48	16,335.30	16,853.46
2	Other Income	33.31	76.62	42.05	212.14	110.64
3	Total Revenue (1+2)	6,681.05	5,180.99	6,151.53	16,547.44	16,964.10
4	Expenses					
	(a) Cost of materials consumed	4,358.18	3,894.63	3,301.44	11,063.93	8,956.75
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods work-in-progress and stock-in trade	0.16	(657.32)	(205.96)	(1,345.90)	(198.36)
	(d) Employee Benefits Expense	424.38	415.11	399.14	1,284.48	1,245.83
	(e) Finance costs	105.45	88.96	134.39	329.86	436.65
	(f) Depreciation and amortisation expense	144.58	143.73	139.87	429.28	416.45
	(g) Other expenses	1,342.27	1,186.53	1,760.64	4,211.45	4,625.42
	Total Expenses - (a to g)	6,375.02	5,071.64	5,529.52	15,973.10	15,482.74
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	306.03	109.35	622.01	574.34	1,481.36
6	Exceptional items	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	306.03	109.35	622.01	574.34	1,481.36
8	Extraordinary Items	-	-	-	-	-
9	Profit before Tax (7-8)	306.03	109.35	622.01	574.34	1,481.36
10	Tax Expenses					
	(1) Current Tax	75.00	35.00	200.00	165.00	500.00
	(2) Deferred Tax	(16.55)	(27.24)	(11.76)	(43.64)	(16.56)
11	Net Profit / (Loss) for the Period (9-10)	247.58	101.59	433.77	452.98	997.92
12	Other Comprehensive Income (OCI): Items that will not be reclassified to profit or Loss: Remeasurement of post-employment benefit obligation (net of tax)	(9.53)	(9.52)	(7.82)	(20.01)	(16.50)
		(9.53)	(9.52)	(7.82)	(20.01)	(16.50)
13	Total comprehensive Income for the period (11+12)	238.05	92.07	425.95	432.97	981.42
14	Paid-up equity share capital (Face Value of Re.10/- each)	302.33	302.33	1.00	302.33	1.00
15	Other equity					
16	Earning Per Equity Share of Rs.10/- each (not annualised)					
	(a) Basic	8.19	3.36	4,337.68	14.98	9,979.24
	(b) Diluted	8.19	3.36	14.35	14.98	33.01




Notes:

- 1 The above Financial Results have been reviewed and recommended by the Audit Committee on 05th February, 2018 and have been approved by the Board of Directors at its meeting held on 05th February, 2018.
- 2 Results for the quarter ended 31st December, 2018 were subjected to 'Limited Review' by the Auditors.
- 3 The Company has adopted Indian Accounting Standards (IND-AS), prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, with effect from 01st April, 2017, with transition date April 1, 2016. The unaudited Financial Results has been prepared by the Company in accordance with IND AS notified under the Company's (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules, 2016. The financial results have been prepared in accordance with recognition and measurement principles laid down in IND AS 34 Interim Financial Reporting.

The Ind AS compliant financial results pertaining to quarter ended 31st December, 2016 has not been subjected to limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs and the same was subjected to review under 'IGAP' by the auditors.

A reconciliation of financial results as reported under Previous Indian GAAP (referred as "IGAAP") and IND-AS is summarised below:

Particulars	(Rs. In Lakhs)	
	Quarter ended 31.12.2016	9 Months Ended 31.12.2016
Net Profit as per previous GAAP (Indian GAAP)	424.68	986.17
Ind AS adjustments:		
Acturial loss on employee defined benefit funds recognised in Other Comprehensive Income	11.95	25.24
Others	(1.15)	(16.59)
Deferred taxes on Ind AS adjustments	(1.71)	3.10
Net Profit as per Ind AS	433.77	997.92
Other Comprehensive Income, net of Income Tax	(7.82)	(16.50)
Total comprehensive Income for the period	425.95	981.42




- 4 These results do not include Ind AS compliant results for the previous year ended 31st March, 2017 as the same is not mandatory as per SEBI Circular dated 5th July,2016.
- 5 The Company has allotted 30,23,387 Equity Shares of Rs. 10/- each, in the month of June, 2017 in pursuance of the scheme of arrangement, to the shareholders of demerged company i.e., SMS Pharmaceuticals Limited,. The existing 10,000 Equity shares of Rs. 10/- each held by the demerged company shall stand cancelled, extinguished and annulled. Hence the value of EPS can't be comparable.
- 6 In accordance with the requirements of Ind AS18, revenue from operations for the quarter ended 31st December,2017 is shown net of Goods and Services Tax (GST). However, net sales for the corresponding quarter and previous 9 Months Ended are shown inclusive of excise duty. Nine months period ended 31st December, 2017 includes excise duty upto 30th June,2017. The following additional information is being provided to facilitate better understanding.

Particulars	(Rs.in Lakhs)		
	Quarter Ended		9 Months Ended
	31.12.2017	30.09.2017	31.12.2016
Revenue from Operations	7,452.86	5,533.45	6,109.48
GST Recovered	805.12	429.07	-
Excise Duty on Sale		-	395.87
Revenue from Operations excluding GST/Excise Duty	6,647.74	5,104.37	5,713.61

- 7 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 8 Figures of previous period have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 05-02-2018



For SMS LIFESCIENCES INDIA LTD

T V S N MURTHY
Managing Director

Limited Review Report

To
The Board of Directors
SMS LIFESCIENCES INDIA LIMITED
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of SMS LIFESCIENCES INDIA LIMITED ("the Company"), for the quarter ended 31st December 2017("the statement"), being submitted by the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.


As stated in Notes of financial statement, we have not performed a review of the figures relating to the corresponding quarter ended 31st December, 2016 including the reconciliation of net profit for the quarter ended 31st December, 2016 between the previous GAAP and the Indian Accounting Standards ("Ind AS")

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No.CIR/CFD/FAC/62/2016 dated 5th July,2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 05-02-2018



For Rambabu & Co.,
Chartered Accountants
Reg. No.0029765

GVL Prasad
Partner
M. No. 026548